Pharmena S.A. (WSE:PHR)

Market Cap	37.98M -22.3%
Revenue (ttm)	1.58M +488.4%
Net Income	-2.77M
EPS	-0.25
Shares Out	11.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,823
Average Volume	3,414
Open	3.410
Previous Close	3.410
Day's Range	3.300 - 3.430
52-Week Range	2.500 - 4.320
Beta	0.58
RSI	45.49
Earnings Date	May 28, 2026

About Pharmena

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmen...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 7
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: PHR

Financial Performance

In 2025, Pharmena's revenue was 1.58 million, an increase of 488.43% compared to the previous year's 268,000. Losses were -2.77 million, 119.4% more than in 2024.